{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=12", "query": { "condition": "Lymphoid Leukemia", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 2901, "total_pages": 291, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid+Leukemia&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:47:20.452Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04762875", "title": "MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Related Donors Donating PBSC to a Family Member", "Healthy Donors", "Acute Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "MGTA-145", "type": "BIOLOGICAL" }, { "name": "Plerixafor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ensoma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 7, "start_date": "2021-06-16", "completion_date": "2022-03-14", "has_results": true, "last_update_posted_date": "2024-11-06", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 8, "location_summary": "Duarte, California • Stanford, California • Atlanta, Georgia + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762875" }, { "nct_id": "NCT07166419", "title": "Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Recurrent Indolent Non-Hodgkin Lymphoma", "Recurrent Lymphoblastic Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive", "Refractory Indolent Non-Hodgkin Lymphoma", "Refractory Lymphoblastic Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Autologous Anti-CD19/CD20/CD22 CAR T-cells", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-01-14", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07166419" }, { "nct_id": "NCT00016172", "title": "ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "picoplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-11", "completion_date": "2002-04", "has_results": false, "last_update_posted_date": "2013-06-18", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016172" }, { "nct_id": "NCT02159495", "title": "Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia in Remission", "Acute Biphenotypic Leukemia", "Early Relapse of Acute Myeloid Leukemia", "Late Relapse of Acute Myeloid Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Blastic Plasmacytoid Dendritic Cell Neoplasm", "Acute Myeloid Leukemia", "Adult Acute Lymphoblastic Leukemia", "Interleukin-3 Receptor Subunit Alpha Positive", "Minimal Residual Disease", "Refractory Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 31, "start_date": "2015-12-15", "completion_date": "2027-07-14", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159495" }, { "nct_id": "NCT01995669", "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Grade 3a Follicular Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2014-05-27", "completion_date": "2023-01-23", "has_results": true, "last_update_posted_date": "2025-06-24", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01995669" }, { "nct_id": "NCT00509691", "title": "Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "cytomegalovirus pp65-specific cytotoxic T lymphocytes", "type": "BIOLOGICAL" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "immunologic technique", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "OTHER" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "2 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2007-06", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509691" }, { "nct_id": "NCT00005797", "title": "Bone Marrow Transplant in Treating Patients With Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Multiple Myeloma and Malignant Plasma Cell Neoplasms", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "busulfan", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "VP-16", "type": "DRUG" }, { "name": "Fractionated Total Body Irradiation (FTBI)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "15 Years to 55 Years" }, "enrollment_count": 125, "start_date": "1993-03", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005797" }, { "nct_id": "NCT03913559", "title": "Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 5, "start_date": "2019-05-14", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 2, "location_summary": "San Diego, California • Memphis, Tennessee", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03913559" }, { "nct_id": "NCT00253513", "title": "Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "fludarabine", "type": "DRUG" }, { "name": "treosulfan", "type": "DRUG" }, { "name": "allogeneic blood or bone marrow transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "60 Years", "sex": "ALL", "summary": "Up to 60 Years" }, "enrollment_count": 60, "start_date": "2005-06", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2012-06-01", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 3, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253513" }, { "nct_id": "NCT01786096", "title": "A Safety Study of SGN-CD19A for Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "Precursor B-cell Lymphoblastic Leukemia-Lymphoma" ], "interventions": [ { "name": "SGN-CD19A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 92, "start_date": "2013-02", "completion_date": "2017-05-30", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-22T09:47:20.452Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786096" } ] }